Search research articles
Contact Us
Filters
Showing results (61-70 of 93) with videos related to
Page
of 10
Sort By:
Cancers
|
December 22, 2019
Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma
Wei Teng, Wen-Juei Jeng, Hwai-I Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 14, 2019
Functional Genomics Identifies Hepatitis-Induced STAT3-TYRO3-STAT3 Signaling as a Potential Therapeutic Target of Hepatoma
Chia-Liang Tsai, Jeng-Shou Chang, Ming-Chin Yu, et al.
The Pharmacogenomics Journal
|
October 16, 2019
A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy
Chen-Chun Lin, Chao-Wei Hsu, Yi-Cheng Chen, et al.
American Journal of Cancer Research
|
May 9, 2022
Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma
Chung-Wei Su, Ming-Mo Hou, Pei-Wei Huang, et al.
Cancers
|
October 26, 2024
Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis
Yu-Chun Hsu, Po-Ting Lin, Wei Teng, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
December 25, 2018
Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients
Ying-Chieh Chen, Wei Teng, Yi-Chung Hsieh, et al.
Cancer Immunology, Immunotherapy : CII
|
January 27, 2026
Non-thyroidal illness syndrome predicts poor prognosis in hepatocellular carcinoma patients treated with atezolizumab and bevacizumab
I-Wen Chen, Cheng-Wei Lin, Po-Ting Lin, et al.
American Journal of Cancer Research
|
November 12, 2021
Complete response at first transarterial chemoembolization predicts favorable outcome in hepatocellular carcinoma
Chien-Wei Peng, Wei Teng, Kar-Wai Lui, et al.
American Journal of Cancer Research
|
December 7, 2023
A combination of locoregional treatment with systemic therapy after atezolizumab plus bevacizumab failure for unresectable hepatocellular carcinoma provides survival benefit
Chung-Wei Su, Wei Teng, Po-Ting Lin, et al.
Journal of Cancer
|
June 22, 2026
<i>GALNT14</i>-rs9679162 Genotypes Predict Post-immunotherapy Side Effect and Survival in Patients with Hepatitis B Virus-related Hepatocellular Carcinoma
Po-Ting Lin, Wei Teng, Wei-Ting Chen, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 93) with videos related to
Sort By:
Page
of 10
Cancers
|
December 22, 2019
Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma
Wei Teng, Wen-Juei Jeng, Hwai-I Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 14, 2019
Functional Genomics Identifies Hepatitis-Induced STAT3-TYRO3-STAT3 Signaling as a Potential Therapeutic Target of Hepatoma
Chia-Liang Tsai, Jeng-Shou Chang, Ming-Chin Yu, et al.
The Pharmacogenomics Journal
|
October 16, 2019
A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy
Chen-Chun Lin, Chao-Wei Hsu, Yi-Cheng Chen, et al.
American Journal of Cancer Research
|
May 9, 2022
Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma
Chung-Wei Su, Ming-Mo Hou, Pei-Wei Huang, et al.
Cancers
|
October 26, 2024
Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis
Yu-Chun Hsu, Po-Ting Lin, Wei Teng, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
December 25, 2018
Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients
Ying-Chieh Chen, Wei Teng, Yi-Chung Hsieh, et al.
Cancer Immunology, Immunotherapy : CII
|
January 27, 2026
Non-thyroidal illness syndrome predicts poor prognosis in hepatocellular carcinoma patients treated with atezolizumab and bevacizumab
I-Wen Chen, Cheng-Wei Lin, Po-Ting Lin, et al.
American Journal of Cancer Research
|
November 12, 2021
Complete response at first transarterial chemoembolization predicts favorable outcome in hepatocellular carcinoma
Chien-Wei Peng, Wei Teng, Kar-Wai Lui, et al.
American Journal of Cancer Research
|
December 7, 2023
A combination of locoregional treatment with systemic therapy after atezolizumab plus bevacizumab failure for unresectable hepatocellular carcinoma provides survival benefit
Chung-Wei Su, Wei Teng, Po-Ting Lin, et al.
Journal of Cancer
|
June 22, 2026
<i>GALNT14</i>-rs9679162 Genotypes Predict Post-immunotherapy Side Effect and Survival in Patients with Hepatitis B Virus-related Hepatocellular Carcinoma
Po-Ting Lin, Wei Teng, Wei-Ting Chen, et al.
Page
of 10